WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) on Friday announced that the FDA has approved Veopoz as the first-ever treatment for adult and pediatric patients with CHAPLE disease.
CHAPLE is an ultra-rare and deadly hereditary immune disease caused by an overactivation of the complement system due to mutations in the CD55 gene.
Veopoz is a fully human monoclonal antibody, that is designed to target complement factor C5, the protein involved in complement system activation.
Copyright(c) 2023 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX